X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (216) 216
male (205) 205
androstenols - therapeutic use (182) 182
androstenes (165) 165
index medicus (145) 145
prostatic neoplasms - drug therapy (121) 121
prostate cancer (81) 81
oncology (80) 80
antineoplastic agents - therapeutic use (75) 75
phenylthiohydantoin - analogs & derivatives (63) 63
abiraterone (57) 57
taxoids - therapeutic use (55) 55
docetaxel (52) 52
orchiectomy (50) 50
androgen antagonists - therapeutic use (48) 48
abiraterone acetate (47) 47
chemotherapy (42) 42
steroid 17-alpha-hydroxylase - antagonists & inhibitors (41) 41
treatment outcome (41) 41
prostatic neoplasms - pathology (40) 40
prostatic neoplasms, castration-resistant - drug therapy (40) 40
phenylthiohydantoin - therapeutic use (39) 39
middle aged (38) 38
urology & nephrology (38) 38
aged (37) 37
androstenols - administration & dosage (35) 35
androstenols - pharmacology (33) 33
prostatic neoplasms - surgery (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
castration (31) 31
animals (30) 30
antitumor-activity (30) 30
clinical trials as topic (30) 30
female (30) 30
tissue extracts - therapeutic use (29) 29
drug resistance, neoplasm (28) 28
mitoxantrone plus prednisone (28) 28
androstenols - adverse effects (27) 27
disease progression (27) 27
metastasis (27) 27
androgen receptor (26) 26
enzalutamide (26) 26
antineoplastic agents, hormonal - therapeutic use (25) 25
i clinical-trial (24) 24
adult (23) 23
increased survival (23) 23
prostate-specific antigen - blood (23) 23
prostatic neoplasms - metabolism (23) 23
aged, 80 and over (22) 22
prostatic neoplasms - mortality (22) 22
sipuleucel-t (22) 22
abridged index medicus (21) 21
cyp17 (21) 21
drug therapy (21) 21
prednisone (21) 21
acetate (20) 20
cabazitaxel (20) 20
castration-resistant prostate cancer (20) 20
survival (20) 20
mitoxantrone (19) 19
pharmacology & pharmacy (19) 19
receptors, androgen - metabolism (19) 19
androgens (18) 18
bone neoplasms - secondary (18) 18
care and treatment (18) 18
medicine, general & internal (18) 18
steroidal inhibitors (18) 18
cancer (17) 17
enzyme inhibitors - therapeutic use (17) 17
neoplasm metastasis (17) 17
phase-ii (17) 17
research (17) 17
testosterone (17) 17
trial (17) 17
immunotherapy (16) 16
mice (16) 16
bone neoplasms - drug therapy (15) 15
clinical trials, phase iii as topic (15) 15
prostatic neoplasms - genetics (15) 15
receptors, androgen - genetics (15) 15
taxoids - administration & dosage (15) 15
therapy (15) 15
antiandrogen withdrawal (14) 14
article (14) 14
expression (14) 14
ketoconazole (14) 14
prostatic neoplasms, castration-resistant - pathology (14) 14
antineoplastic agents - pharmacology (13) 13
carcinoma (13) 13
double-blind (13) 13
drug resistance, neoplasm - genetics (13) 13
health aspects (13) 13
randomized controlled trials as topic (13) 13
urology (13) 13
androgens - metabolism (12) 12
cancer therapies (12) 12
cancer vaccines - therapeutic use (12) 12
denosumab (12) 12
disease-free survival (12) 12
neoplasms, hormone-dependent - drug therapy (12) 12
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (199) 199
German (10) 10
French (6) 6
Italian (4) 4
Hungarian (2) 2
Japanese (2) 2
Finnish (1) 1
Polish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
CA Cancer Journal for Clinicians, ISSN 0007-9235, 09/2012, Volume 62, Issue 5, pp. 299 - 308
There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than... 
GROWTH FACTOR/SCATTER FACTOR | LEUKEMIA GROUP-B | MITOXANTRONE PLUS PREDNISONE | PHASE-II TRIAL | ONCOLOGY | ORAL ESTRAMUSTINE PHOSPHATE | ABIRATERONE ACETATE | END-POINTS | RANDOMIZED CONTROLLED-TRIAL | ANTITUMOR-ACTIVITY | SIPULEUCEL-T | Castration - adverse effects | Prostate-Specific Antigen | Anilides - therapeutic use | Taxoids - pharmacology | Phenylthiohydantoin - therapeutic use | Cancer Vaccines - pharmacology | Humans | Tissue Extracts - pharmacology | Male | Antineoplastic Agents - therapeutic use | Androstenols - therapeutic use | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Radiopharmaceuticals - pharmacology | Pyridines - therapeutic use | Phenylthiohydantoin - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Radium - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | RANK Ligand - antagonists & inhibitors | Anilides - pharmacology | Pyridines - pharmacology | Radiopharmaceuticals - therapeutic use | Care and treatment | Drug therapy | Drug resistance | Laws, regulations and rules | Prostate cancer | Drug approval | Clinical trials | Chemotherapy | Castration | Pathogenesis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1028 - 1038
Journal Article